Miriam E. Tucker - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Miriam E. Tucker's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Miriam E. Tucker
Verified
Contributing Writer, Medscape
Washington
Beats
Grief loss recovery death & dying.Rituals and healing.
Content
By Miriam E. Tucker Verified| Medscape Verified New data documented dramatic shifts in prescribing for both type 2 diabetes (T2D) and weight loss, particularly with the uptake of tirzepatide (Lilly) and declines in the use of older agents
By Miriam E. Tucker Verified| Medscape Verified Orforglipron, Eli Lilly’s investigational oral glucagon-like peptide 1 receptor agonist (GLP-1 RA), achieved positive phase 3 results for both A1c and weight loss, according to top-line data released by the company. The findings came from Lilly’s ACHIEVE-1, the first of seven phase 3 trials examining the safety and efficacy of orforglipron in over 6000 patients with diabetes and obesity
Company Info
Medscape
Washington, D.C., United States